Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Glucose-dependent insulinotropic polypeptide augmentation of insulin
Ranked by 2024 Global Sales: 1 Ozempic (semaglutide) $16.7 Bn | Novo Nordisk 2 Mounjaro (tirzepatide) $11.5 Bn | Eli Lilly 3 Jardiance (empagliflozin) $9.5 Bn | Boehringer Ingelheim & Eli Lilly 4 Forxiga (dapagliflozin) $7.7 Bn | AstraZeneca 5 Trulicity (dulaglutide) $5.3 Bn | Eli Lilly 6 Rybelsus (semaglutide) $3.2 Bn | Novo Nordisk 7 Humalog (insulin lispro) $2.3 Bn | Eli Lilly 8 NovoRapid (insulin aspart) $2.3 Bn | Novo Nordisk 9 Jentadueto / Trajenta (linagliptin) $1.8 Bn | Boehringer Ingelheim Lantus (insulin glargine) $1.7 Bn | Sanofi Key Insight: The dominance of incretin-based therapies underscores a clear industry shift toward multi-benefit, patient-centric treatments
Discuss any concerns with your PlexusDx provider before starting
Si les bnfices sont clairs, il ne faut pas ignorer les ractions que votre corps pourrait manifester lors dune cure
Phase 2 trials show an average weight loss of 24% after 48 weeks on the highest dose of 12mg
More serious but less common adverse effects observed across the incretin drug class and under investigation for retatrutide include: Pancreatitis : Seek urgent medical attention if you experience severe, persistent abdominal pain, particularly if it radiates to the back
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
